219 related articles for article (PubMed ID: 21514084)
1. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial.
Stone GW; Rizvi A; Sudhir K; Newman W; Applegate RJ; Cannon LA; Maddux JT; Cutlip DE; Simonton CA; Sood P; Kereiakes DJ;
J Am Coll Cardiol; 2011 Jun; 58(1):19-25. PubMed ID: 21514084
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
3. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial).
Smits PC; Kedhi E; Royaards KJ; Joesoef KS; Wassing J; Rademaker-Havinga TA; McFadden E
J Am Coll Cardiol; 2011 Jun; 58(1):11-8. PubMed ID: 21514083
[TBL] [Abstract][Full Text] [Related]
4. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).
Kereiakes DJ; Cutlip DE; Applegate RJ; Wang J; Yaqub M; Sood P; Su X; Su G; Farhat N; Rizvi A; Simonton CA; Sudhir K; Stone GW
J Am Coll Cardiol; 2010 Dec; 56(25):2084-9. PubMed ID: 21144968
[TBL] [Abstract][Full Text] [Related]
6. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
[TBL] [Abstract][Full Text] [Related]
7. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
Kereiakes DJ; Sudhir K; Hermiller JB; Gordon PC; Ferguson J; Yaqub M; Sood P; Su X; Yakubov S; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2010 Dec; 3(12):1229-39. PubMed ID: 21232716
[TBL] [Abstract][Full Text] [Related]
8. Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial).
Ng VG; Lansky AJ; Hermiller JB; Farhat N; Applegate RJ; Yaqub M; Sood P; Su X; Simonton CA; Sudhir K; Stone GW
Am J Cardiol; 2011 Mar; 107(6):841-8. PubMed ID: 21255760
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials.
Onuma Y; Serruys PW; Kukreja N; Veldhof S; Doostzadeh J; Cao S; Stone GW;
Eur Heart J; 2010 May; 31(9):1071-8. PubMed ID: 20118171
[TBL] [Abstract][Full Text] [Related]
10. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus.
Stone GW; Kedhi E; Kereiakes DJ; Parise H; Fahy M; Serruys PW; Smits PC
Circulation; 2011 Aug; 124(8):893-900. PubMed ID: 21824922
[TBL] [Abstract][Full Text] [Related]
11. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial.
Applegate RJ; Hermiller JJ; Sanz M; Doostzadeh J; Pierson W; Su X; Lansky AJ; Sudhir K; Stone GW
EuroIntervention; 2010 Sep; 6(4):437-46. PubMed ID: 20884430
[TBL] [Abstract][Full Text] [Related]
12. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial.
Brener SJ; Kereiakes DJ; Simonton CA; Rizvi A; Newman W; Mastali K; Wang JC; Caputo R; Smith RS; Ying SW; Cutlip DE; Stone GW
Am Heart J; 2013 Dec; 166(6):1035-42. PubMed ID: 24268218
[TBL] [Abstract][Full Text] [Related]
13. Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial).
Applegate RJ; Yaqub M; Hermiller JB; Sood P; Yu S; Doostzadeh J; Williams JE; Farhat N; Caputo R; Lansky AJ; Cutlip DE; Sudhir K; Stone GW
Am J Cardiol; 2011 Mar; 107(6):833-40. PubMed ID: 21247538
[TBL] [Abstract][Full Text] [Related]
14. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.
Räber L; Magro M; Stefanini GG; Kalesan B; van Domburg RT; Onuma Y; Wenaweser P; Daemen J; Meier B; Jüni P; Serruys PW; Windecker S
Circulation; 2012 Mar; 125(9):1110-21. PubMed ID: 22302840
[TBL] [Abstract][Full Text] [Related]
15. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease.
Nikolsky E; Lansky AJ; Sudhir K; Doostzadeh J; Cutlip DE; Piana R; Su X; White R; Simonton CA; Stone GW
Am Heart J; 2009 Oct; 158(4):520-526.e2. PubMed ID: 19781409
[TBL] [Abstract][Full Text] [Related]
16. Percutaneous coronary intervention with second-generation paclitaxel-eluting stents versus everolimus-eluting stents in United States contemporary practice (REWARDS TLX Trial).
Waksman R; Ghali M; Goodroe R; Ryan T; Turco M; Ring M; McGarry T; Dobies D; Shammas N; Steinberg DH; Swymelar S; Kaneshige K; Torguson R
Am J Cardiol; 2012 Oct; 110(8):1119-24. PubMed ID: 22762711
[TBL] [Abstract][Full Text] [Related]
17. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.
Beijk MA; Piek JJ
Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467
[TBL] [Abstract][Full Text] [Related]
18. Clinical safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents in patients with coronary artery disease.
Zhang F; Dong L; Qian J; Ge J
Ann Med; 2011 Feb; 43(1):75-9. PubMed ID: 21171912
[TBL] [Abstract][Full Text] [Related]
19. Performance of everolimus-eluting versus paclitaxel-eluting coronary stents in small vessels: results from the SPIRIT III and SPIRIT IV clinical trials.
Ito H; Hermiller JB; Yaqub M; Newman W; Sood P; Wang JC; Cannon L; Maddux JE; Sudhir K; Stone GW
J Interv Cardiol; 2011 Dec; 24(6):505-13. PubMed ID: 21919955
[TBL] [Abstract][Full Text] [Related]
20. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.
Onuma Y; Kukreja N; Piazza N; Eindhoven J; Girasis C; Schenkeveld L; van Domburg R; Serruys PW;
J Am Coll Cardiol; 2009 Jul; 54(3):269-76. PubMed ID: 19589442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]